Results 61 to 70 of about 2,379 (179)

Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes

International Journal of Neonatal Screening
CFTR modulators have transformed the clinical evolution of patients with CF. The number of pregnancies is increasing in women with CF, most of whom are now treated with CFTR modulators such as elexacaftor/tezacaftor/ivacaftor (ETI) or Tezacaftor ...
Louis Domenach, Adrien Pagin, Camille Cisterne, Marie-Pierre Audrezet, Laure Couderc, Laetitia Monteil, Léa Roditis, Marlène Murris, Julie Macey, Michael Fayon, Stéphanie Bui, Marie-Pierre Reboul   +11 more
doaj   +1 more source

Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions

Pregnancy, Volume 2, Issue 4, July 2026.
Abstract Background The consequences of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein dysfunction or absence begin during fetal development, with pancreatic, intestinal, hepatobiliary, and reproductive manifestations evident at birth.
Hiba J. Mustafa, Yair J. Blumenfeld, Ramen H. Chmait, Jennifer L. Taylor‐Cousar, Jordana E. Hoppe, Stacey L. Martiniano, Angela Metcalf, Scott D. Sagel, Edith T. Zemanick, Alireza A. Shamshirsaz, Sylvia E. Szentpetery, Aaron T. Trimble, Elizabeth B. Burgener, Carmen Luna‐Paredes, Isabelle Sermet‐Gaudelus, Michael V. Zaretsky   +15 more
wiley   +1 more source

Delayed Diagnosis of Cystic Fibrosis and Nontuberculous Mycobacterial Infection in Refractory CRSwNP

Respirology Case Reports, Volume 14, Issue 7, July 2026.
This case describes a 31‐year‐old woman with treatment‐resistant sinus disease in which a delayed diagnosis of CF led to lung complications. It emphasises the importance of considering underlying causes like CF in unexplained, treatment‐resistant cases of chronic rhinosinusitis.
Robert Greig, Philipp Suter, Rory Chan, David Connell, Brian Lipworth   +4 more
wiley   +1 more source

ID-44 Perfil de Distribuição da Terapia Tripla para Tratamento da Fibrose Cística no 2º Semestre de 2024

Jornal de Assistência Farmacêutica e Farmacoeconomia
Objetivo: Analisar o perfil de distribuição do medicamento que representa uma tripla terapia para fibrose cística, consistindo na associação elexacaftor, tezacaftor e  ivacaftor, possuindo duas apresentações: elexacaftor 50 mg + tezacaftor 25 mg ...
Flavia Kimura Okamoto, Marcelo Azevedo Coutinho   +1 more
doaj   +1 more source

Comparison of Single‐Breath and Multi‐Breath Xe‐MRI in the Longitudinal Assessment of Treatment in Children With Cystic Fibrosis

Journal of Magnetic Resonance Imaging, Volume 63, Issue 6, Page 1652-1661, June 2026.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) is a current standard therapy for pediatric cystic fibrosis (CF). Multiple‐breath washout 129Xe MRI (MBW Xe‐MRI) is improved following 1 month of treatment. However, the utility of MBW Xe‐MRI over extended ETI treatment and its comparison to single‐breath Xe‐MRI and pulmonary function tests ...
Faiyza S. Alam, Samal Munidasa, Brandon Zanette, Daniel Li, Sharon Braganza, Felix Ratjen, Giles Santyr   +6 more
wiley   +1 more source

Rethinking hyperbilirubinemia: Gilbert syndrome in children with cystic fibrosis, a case report

Respiratory Medicine Case Reports
Cystic Fibrosis leads to liver complications, including cystic fibrosis liver disease but hyperbilirubinemia in CF patients on CFTR modulators is less understood.
Yara Salameh, John Lyles, Shatha Yousef
doaj   +1 more source

Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis [PDF]

Canadian Journal of Ophthalmology, 2022
Matthew J. Miller, Rod Foroozan
openaire   +2 more sources

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation

Health Technology Assessment
Background Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system ...
Steven J Edwards, Benjamin G Farrar, Kate Ennis, Nicole Downes, Victoria Wakefield, Isaac Mackenzie, Archie Walters, Tracey Jhita   +7 more
doaj   +1 more source

The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study

BMC Pulmonary Medicine
Background Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients.
Nela Stastna, Lenka Hrabovska, Pavel Homolka, Lukas Homola, Michal Svoboda, Kristian Brat, Libor Fila   +6 more
doaj   +1 more source

Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan within one international nonproprietary name

Лечащий Врач
Background. Due to the widespread use of targeted therapy drugs with various trade names in the treatment of cystic fibrosis, there is a need for a clinical evaluation of the results of treatment with these drugs and their tolerability and safety within ...
O. G. Pyaterkina, O. A. Karpova, G. R. Begieva, I. I. Zakirov, D. T. Shayapova, Ch. A. Bagauova   +5 more
doaj   +1 more source